In a recent article by Kabat and Knapp,' the use of prostigmine in the treatment of poliomyelitis has been discussed. Their approach to therapy was based on the Kenny concept of the disease. From observations on a series of 20 patients with poliomyelitis, most of whom were in the subacute stage of the disease, it was concluded that prostigmine increased the range of passive motion, decreased or eliminated deformities in some instances by relaxation of hypertonus, and in a few cases improved the active motion. Hot fomentations were used during the time that the drug was administered.
From June through November 1943 we have had an opportunity of seeing nearly 200 cases of acute poliomyelitis in the New Haven Hospital. In view of the improvement noted by Kabat and Knapp with prostigmine we felt justified in trying this drug on a small selected group of our cases. The Kenny method was used in the treatment of all our patients. Ultimately 12 patients in the early stages of the disease received prostigmine as an additional form of therapy.
The 12 patients whom we chose all showed marked spasm of the back muscles and hamstrings, and 10 of these had some degree of paralysis in the legs. There were two reasons why we did not have a control group to compare with those patients treated with prostigmine. The first was that the clinical findings in poliomyelitis are so different in each case that a small series would have little significance, while in the second place there were not enough patients with the same type of involvement who could be counted on to cooperate or who would be available for the whole test period.
The essential difference between our series of patients and those of Kabat and Knapp was that our patients were started on prostigmine treatment earlier in the course of the disease. The average period from the onset of symptoms until prostigmine was given was 1 8 days, and the patients averaged two weeks of the Kenny treatment during this period. In the series of Kabat and Knapp there was an average period of 6 months before prostigmine was given.
Our procedure was as follows:
(1) The range of passive motion of the involved extremity was measured in degrees using the goniometer.
(2) A subcutaneous injection of prostigmine methylsulfate was given.
(3) The range of motion was again measured after one hour.
(4) Routine Kenny treatment was then resumed.
(5) Prostigmine was given orally, three times a day for 28 days.
(6) The range of passive motion was measured for the third time.
The dosages of prostigmine, and of atropine when it was given, were approximately the same as those used by Kabat and Knapp. A subcutaneous dose of 1.5 mg. of prostigmine methylsulfate and 0.6 mg. of atropine sulfate was given to the adults. Older children were given 1.125 mg. of prostigmine and 0.4 mg. of atropine. Younger children were given 0.5 mg. of prostigmine and no atropine. No Kenny packs were given during the hour following the subcutaneous dose. The oral doses of prostigmine bromide were started at roughly one-third the average maximum dose for the patient's age and were rapidly increased to tolerance. The average adult dose was 45 mg. of prostigmine bromide and 0.6 mg. of atropine given orally three times a day. The two small children were each given 30 mg. three times a day without atropine. The largest total oral dose of prostigmine given an adult during the 28-day period was 3.24 gm., the smallest 2.3 gm. The largest total dose given a child was 2.68 gm., the smallest 1.87 gm.
The immediate reactions to a test dose of prostigmine glven subcutaneously were similar to those noted by Kabat and Knapp. All 12 patients had fascicular muscle twitchings within one-half hour after the injection. Eight had mild twitchings while four had severe ones. These had disappeared by the end of one hour. Two patients complained of a feeling of numbness at the base of the tongue. Two had some mild abdominal pain, two had nausea and one of these vomited. The child who vomited was a 7-year-old girl who had received 1.1 mg. of prostigmine and 0.4 One patient developed hematuria on the twenty-third day of treatment and the drug was discontinued. Two days later she had no gross or microscopic blood in the urine and has had none since. This patient was a 27-year-old female who was four months pregnant at the time. She had had two previous pregnancies without complications and had never before had hematuria. This was the only patient who received less than the 28-day period of therapy with prostigmine.
One patient, who previously had been completely unable to move one lower extremity was able to bend his knee one hour after the injection of prostigmine.
Within a few days after the onset of prostigmine therapy the adult patients volunteered the information that they could move about in bed more freely and had a subjective feeling of more strength in performing purposeful motions. An example of this was one patient, an adult female, who one week after the beginning of treatment was able to turn over in bed by herself, whereas she had previously been unable to do so. Table 1 shows the changes in the range of passive motion that were found in these patients. It can be seen from these figures that the most marked increase in passive motion occurred one hour after the initial subcutaneous injection of prostigmine. In general, there was not so marked an improvement after the 28-day period of oral therapy, even though the Kenny treatment was being carried on during this period. It can be seen that the changes vary considerably in the different muscle groups; this same phenomenon was noted by Kabat and Knapp in their series.
Two of our adult patients were given a second subcutaneous dose of the drug two weeks after the first injection. The range of motion was then measured one hour later, just as after the initial injection. This was done to see if the subcutaneous injection was more effective than the oral method. Table 2 shows that this second injection did not have much effect in these two patients and suggests that the improvement obtained by the first subcutaneous dose could probably be maintained just as well by the oral as by the subcutaneous administration of the drug.
In order to attempt a comparison of our results with those of Table 3 shows the results of this comparison. 2. An effort has been made to compare our results with those of Kabat and Knapp.
3. There was a definite relief of muscle spasm, as indicated by an increased range of passive motion, in the lower extremities following the initial subcutaneous injection of prostigmine methylsulfate. This decrease in spasm occurred in all 12 patients and was recorded one hour after the injection. During this hour no packs were used.
4. The difficulty in determining the effect of the oral administration of prostigmine on muscle spasm after the 4-week period is obvious. These patients might have had a decrease in muscle spasm without any therapy during this period or the hot packs may have relieved the spasm. In any event, after a period of 4 weeks of prostigmine given orally, there was, in general, little further decrease in spasm. Six of the twelve cases showed less spasm.
5. In the series of Kabat and Knapp there was a more marked improvement following the oral drug than in our patients. However, ours were started on prostigmine much earlier in the course of the disease than were those of Kabat and Knapp and this fact may account for the difference.
6. We were not able to note the effect of prostigmine in contractures because our patients were all in the early stage of the disease.
7. A period of about 8 months has elapsed since this study was made and these patients have continued to receive the Kenny treatment without prostigmine. They have shown a gradual relief of muscle spasm and in most cases an improvement in musde power. Whether or not in the long run this relief was facilitated by prostigmine is difficult to determine.
